Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2010-11-22
pubmed:abstractText
Patients with mantle cell lymphoma (MCL) typically respond to initial treatment but subsequently relapse. This pattern suggests that a population of MCL cells is both drug resistant and capable of clonogenic growth. The intracellular enzyme retinaldehyde dehydrogenase (ALDH) provides resistance to several toxic agents. ALDH can also identify stem cells in normal adult tissues and tumorigenic cancer stem cells in several human malignancies. We studied ALDH expression in MCL and found small populations of ALDH(+) cells that were highly clonogenic. Moreover, ALDH(+) MCL cells were relatively quiescent and resistant to a wide range of agents. Normal B cells can be activated by specific unmethylated cytosine-phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic CpG oligonucleotide 2006 (CpG) reduced the frequency of quiescent ALDH(+) MCL cells, induced terminal plasma cell differentiation, and limited tumor formation in vitro and in vivo. Treatment with CpG also significantly enhanced the activity of the proteasome inhibitor bortezomib that was associated with induction of the unfolded protein response. Our data suggest that CpG may target clonogenic and resistant ALDH(+) cells as well as improve the activity of proteasome inhibitors in MCL.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
18
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4185-91
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:20570863-Aldehyde Dehydrogenase, pubmed-meshheading:20570863-Animals, pubmed-meshheading:20570863-Boronic Acids, pubmed-meshheading:20570863-Cell Differentiation, pubmed-meshheading:20570863-Cell Line, Tumor, pubmed-meshheading:20570863-Cell Proliferation, pubmed-meshheading:20570863-Clone Cells, pubmed-meshheading:20570863-Drug Resistance, Neoplasm, pubmed-meshheading:20570863-Drug Screening Assays, Antitumor, pubmed-meshheading:20570863-Humans, pubmed-meshheading:20570863-Isoenzymes, pubmed-meshheading:20570863-Lymphocyte Activation, pubmed-meshheading:20570863-Lymphoma, Mantle-Cell, pubmed-meshheading:20570863-Mice, pubmed-meshheading:20570863-Oligodeoxyribonucleotides, pubmed-meshheading:20570863-Plasma Cells, pubmed-meshheading:20570863-Proteasome Endopeptidase Complex, pubmed-meshheading:20570863-Pyrazines, pubmed-meshheading:20570863-Retinal Dehydrogenase, pubmed-meshheading:20570863-Toll-Like Receptor 9, pubmed-meshheading:20570863-Unfolded Protein Response
pubmed:year
2010
pubmed:articleTitle
Mantle cell lymphoma activation enhances bortezomib sensitivity.
pubmed:affiliation
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural